1/21/2021 8:59:19 AM
Merus Prices Public Offering Of 4.85 Mln Common Shares At $24.75 Per Share
1/19/2021 6:31:27 AM
Lilly, Merus NV Collaborate To Discover Novel T-Cell Re-Directing Bispecific Antibody Therapies
12/17/2020 8:11:57 AM
Merus And Sema4 Enter Agreement To Support Phase 1/2 Clinical Trial Of Zenocutuzumab
7/27/2020 8:24:36 AM
Merus Announces FDA Orphan Drug Designation Of Zenocutuzumab For Treatment Of Pancreatic Cancer
7/27/2020 8:23:33 AM
Merus Names Andrew Joe Chief Medical Officer
12/16/2019 8:45:44 AM
Merus: Ton Logtenberg To Step Down; Bill Lundberg Nominated To Be CEO
5/31/2019 7:35:35 AM
Wedbush Is Raising Merus B.V. (MRUS) FY19 Rev. Estimate To 29.2 M From 16.6 M
5/31/2019 7:35:24 AM
Wedbush Is Increasing Merus B.V. (MRUS) Q4 19 Rev. Estimate To 7.2 M From 4.2 M
5/31/2019 7:35:19 AM
Wedbush Is Raising Merus B.V. (MRUS) Q3 19 Rev. Estimate To 7.2 M From 4.2 M
5/31/2019 7:35:06 AM
Wedbush Is Raising Merus B.V. (MRUS) Q2 19 Rev. Estimate To 7.2 M From 4.2 M
5/31/2019 7:34:40 AM
Wedbush Is Increasing Merus B.V. (MRUS) FY19 Estimate To -1.54 From -2.64
5/31/2019 7:34:28 AM
Wedbush Is Raising Merus B.V. (MRUS) Q4 19 Estimate To -0.46 From -0.72
5/31/2019 7:33:54 AM
Wedbush Is Increasing Merus B.V. (MRUS) Q3 19 Estimate To -0.40 From -0.66
5/31/2019 7:33:38 AM
Wedbush Is Increasing Merus B.V. (MRUS) Q2 19 Estimate To -0.41 From -0.67
5/31/2019 7:33:04 AM
Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $25 Price Target
1/7/2019 7:03:34 AM
Merus Says FDA Accepted IND Application For MCLA-145